Background
==========

Breast cancer is a leading cancer in women \[[@B1]\]. About 10-20% of breast cancer cases are family clustered, with multiple family members affected by the disease \[[@B2]\]. Genetic predispositions are the major risk factor for the disease. However, the genetic predispositions are currently known for only 30-40% of the familial breast cancer disease families. The remaining 60-70% of women with familial breast cancer have unknown predispositions and are diagnosed with *BRCAx,* for their unknown predisposition of familial breast cancer \[[@B3]\]. It is estimated the "*missing"* heredity trait for *BRCAx* families likely consists of thousands of rare variants, each presenting a minor disease risk \[[@B4]\]. Indeed, broadly screening the variants across disease populations has uncovered multiple new genetic predispositions for familial breast cancer. A consistent pattern among these newly classified predispositions is that they are always present at very-low frequencies in the given disease population \[[@B5]-[@B10]\]. Their extreme rarity implies that a greater sampling size of disease populations is required to identify the germline predispositions \[[@B10]\]. However, such an expansion is deemed to increase the complexity of data analysis, experimental costs, and time needed. As such, focusing only on the rare variants will not likely be able to determine the entire spectrum of genetic predispositions for *BRCAx* familial breast cancer families. New alternative hypotheses and approaches must be explored to improve the situation. For example, mosaic mutation has implications as potential predispositions for familial breast cancer \[[@B11]\].

Familial breast cancer is defined as an autosomal dominant genetic disease \[[@B12]\]. Although incidences of breast cancer often exhibit atypical Mendelian patterns due to the factors such as low penetrance of genetic predispositions, the predisposition in a disease-prone family is expected to transmit across generations and shared between family members. Focusing on each disease family with a history of the disease is expected to improve the chance to detect the predisposition in a family compared to screening the disease population of pooled cases without family relationships, which can dilute the predisposition highly prevalent in a disease family into insignificant level.

We hypothesize that the unknown predispositions for many *BRCAx* familial breast cancer are specific to each family with a history of the disease. Our previous exome study of a *BRCAx* familial breast cancer family shows the presence of rich genetic variants \[[@B13]\]. In the present study, we expand the exome sequencing study by analyzing three families with *BRCAx* familial breast cancer; 17 members had cancer, and five members were without cancer. Our study also includes 22 probands of *BRCAx* familial breast cancer. Our study reveals the presence of family-specific, novel, deleterious genetic variants as putative genetic predispositions in each family with *BRCAx* familial breast cancer.

Methods
=======

Use of human subjects
---------------------

The use of the patient samples for the study was approved by the Institutional Review Boards (IRB) of Creighton University School of Medicine (\#00-12265 ) and University of Nebraska Medical Center (718-11-EP). All subjects signed the Consent to Participate Form for cancer genetic study.

Individuals from three families with *BRCAx* breast cancer were used to generate exome sequences as we have previously described \[[@B13]\]. *Family I* included six individuals with breast cancer and two individuals without breast cancer. *Family II* included five individuals with breast cancer, one obligate carrier and two individuals without breast cancer. *Family III* included five individuals with breast cancer and one individual without breast cancer. Additionally, 22 probands for *BRCAx* familial breast cancer were included in exome sequencing. All cases used in the study were *BRCA1*-negative, and *BRCA2*-negative, 41 were female and 3 were male, the average age is 42 years old (Figure [1](#F1){ref-type="fig"}, Table [1](#T1){ref-type="table"}).

![**Pedigrees of the three families used in the study.** BC (breast cancer), Bt (brain tumor), CRC (colorectal cancer), Lu (lung cancer), En (endometrium cancer), Ki (kidney cancer), Lym (lymphoma), NHL (non-Hodgkin lymphoma), OC (ovarian cancer), Pro (prostate cancer). Sar (sarcoma), Sk (skin cancer).](1471-2407-14-470-1){#F1}

###### 

BRCAx familial breast cancer cases used in the study

  **Family**   **Cancer type**     **Pathology**                    **BRCA1/2**    **Exome**                                
  ------------ ------------------- -------------------------------- ------------- ------------ --------------- ------ ----- ---------
  Family 1                                                                                                                       
   1           Breast              Infiltrating ductal              **-**          42,973,730   4,340,346,730   97.6   70    184,865
   2           Breast              Not available                    *-*            40,158,059   4,055,963,959   98.3   65    152,692
   3           Breast              Infiltrating ductal              **-**          46,240,754   4,670,316,154   97.2   75    176,554
   4           Prostate            Adenocarcinoma                   **-**          23,418,595   2,365,278,095   98.1   38    207,103
   5           No Cancer                                            **-**          40,313,161   4,071,629,261   98.0   66    213,347
   6           Breast, Colon       Adenocarcinoma                   **-**          17,496,012   1,767,097,212   97.9   28    183,741
   7           Brain               Not available                    **-**          36,166,319   3,652,798,219   99.5   59    171,425
   8           Breast              Adenocarcinoma                   **-**          27,830,687   2,810,899,387   96.3   45    104,343
  Family 2                                                                                                                       
   1           Breast, Breast      Medullary, infiltrating ductal   **-**          33,419,098   3,375,328,898   92.9   54    113,079
   2           Obligated carrier                                    **-**          27,261,117   2,753,372,817   92.4   44    115,328
   3           Breast              Infiltrating ductal              **-**          40,973,473   4,138,320,773   99.6   67    127,272
   4           Breast              Ductal carcinoma in situ         **-**          29,561,523   2,985,713,823   91.5   48    108,655
   5           Breast              Infiltrating ductal              **-**          25,790,969   2,604,887,869   93.1   42    84,687
   6           Breast              Infiltrating ductal              **-**          37,657,589   3,803,416,489   91.6   61    139,891
   7           No Cancer                                            **-**          17,433,912   1,760,825,112   91.6   28    131,786
   8           No Cancer                                            **-**          35,977,512   3,633,728,712   97.3   59    128,680
  Family 3                                                                                                                       
   1           Endometrial         Adenocarcinoma                   **-**          33,662,978   3,399,960,778   93.2   55    129,754
   2           Breast, Skin        Basal, infiltrating ductal       **-**          29,648,460   2,994,494,460   98.3   48    198,862
   3           No Cancer                                            **-**          53,411,156   5,394,526,756   98.8   87    193,017
   4           Breast              Infiltrating ductal              **-**          31,736,845   3,205,421,345   98.3   52    130,941
   5           Breast              Ductal carcinoma in situ         **-**          35,014,538   3,536,468,338   98.4   57    129,754
   6           Breast              Not available                    **-**          38,418,769   3,880,295,669   97.5   62    161,953
  Probands                                                                                                                       
   1           Breast              Ductal carcinoma in situ         **-**          17,832,681   1,801,100,781   93.1   29    109,864
   2           Breast              Invasive ductal carcinoma        **-**          36,166,319   3,652,798,219   99.5   59    142,155
   3           Breast              Invasive ductal carcinoma        **-**          50,944,516   5,145,396,116   98.4   83    152,125
   4           Breast              Invasive ductal carcinoma        **-**          43,889,986   4,432,888,586   99.6   71    169,633
   5           Breast              Invasive ductal carcinoma        **-**          40,125,408   4,052,666,208   99.5   65    153,511
   6           Breast              Invasive lobular carcinoma       **-**          31,798,628   3,211,661,428   97.5   52    119,875
   7           Breast              Invasive ductal carcinoma        **-**          49,739,415   5,023,680,915   99.6   81    113,058
   8           Breast              Invasive ductal carcinoma        **-**          63,352,269   6,398,579,169   99.6   103   99,732
   9           Breast              Invasive ductal carcinoma        **-**          43,744,840   4,418,228,840   99.5   71    149,873
   10          Breast              Invasive ductal carcinoma        **-**          43,573,311   4,400,904,411   99.6   71    141,236
   11          Breast              Invasive ductal carcinoma        **-**          40,938,838   4,134,822,638   99.3   67    143,262
   12          Breast              Ductal carcinoma in situ         **-**          36,258,870   3,662,145,870   99.6   59    138,018
   13          Breast              Ductal carcinoma in situ         **-**          34,550,745   3,489,625,245   99.4   56    146,858
   14          Breast              Invasive ductal carcinoma        **-**          50,295,200   5,079,815,200   99.5   82    156,666
   15          Breast              Invasive ductal carcinoma        **-**          60,736,566   6,134,393,166   99.7   99    115,909
   16          Breast              Invasive ductal carcinoma        **-**          57,383,360   5,795,719,360   99.6   93    120,945
   17          Breast              Invasive ductal carcinoma        **-**          44,922,611   4,537,183,711   99.6   73    110,503
   18          Breast              Invasive ductal carcinoma        **-**          33,883,509   3,422,234,409   99.4   55    131,955
   19          Breast              Invasive ductal carcinoma        **-**          49,729,619   5,022,691,519   99.5   81    146,665
   20          Breast              Invasive ductal carcinoma        **-**          63,184,143   6,381,598,443   99.6   103   119,680
   21          Breast              Invasive ductal carcinoma        **-**          28,002,381   2,828,240,481   99.6   46    86,924
   22          Breast              Invasive ductal carcinoma        **-**          47,794,798   4,827,274,598   99.5   78    112,030
  Average      38,941,211          3,933,062,277                    97.7               63          140,187                       

Exome sequencing
----------------

For each sample, exome sequencing used DNA from blood cells. Exome libraries were constructed using the TruSeq Exome Enrichment Kit (62 Mb, Illumina, San Diego, CA) as per manufacturer's procedures. Exome sequences were collected with a HiSeq™ 2000 sequencer (Illumina, San Diego, CA) with paired-end (2 × 100). All exome data were deposited in the Sequence Read Archive (SRA) database in the National Center for Biotechnology Information (NCBI) (Accession numbers SAMN02404413- SAMN02404456).

Exome sequence mapping and variant calling
------------------------------------------

Exome sequences were mapped to the human genome reference sequence hg19 by Bowtie2 with default parameters in paired mode \[[@B14]\]. The subsequent SAM files were converted to BAM files. Duplicates were removed using Picard (<http://picard.sourceforge.net>). The mapped reads were locally realigned using the genome mapping tool RealignerTargetCreator from the Genome Atlas Tool Kit (GATK) \[[@B15]\]. The base quality scores were recalibrated using BaseRecalibrator (GATK), with NCBI dbSNP build 137, in the GATK resource bundles for reference sequence hg19. VarScan 2 was used for variant calling, \[[@B16]\]. VarScan 2 was run on pileup data generated from BAM files using SAMtools utilities \[[@B17]\]. The mpileup command, with --B parameter to disable base alignment quality (BAQ) computation, and the default parameters were used, with the minimum read depth at 10 and the minimum base quality at 30. The called variants were annotated with ANNOVAR using the software-provided databases of the Reference Sequence (RefSeq; NCBI), dbSNP 137, the 1000 Genomes Project, and the NIH Heart, Lung and Blood Institute (NHLBI) Exome Sequencing Project (ESP) 6500 (<http://evs.gs.washington.edu>).

Those that matched in the databases were classified as known variants and removed. Family-specific normal variants were eliminated by removing the variants shared between the affected and the unaffected family members in each family. The remaining novel variants were classified into synonymous, non-synonymous, splicing site change, stop gain- or loss groups. The variants causing synonymous changes were then removed. For the remaining variants, PolyPhen-2 was used to identify variants causing deleterious effects in the affected genes \[probably damaging score: 0.909-1; possibly damaging score: 0.447 - 0.908; Benign score: 0 - 0.446; HumVar score: \[[@B18]\]. The variants defined as benign were removed. These processes generated a list of novel, deleterious variants only present in the cancer-affected family members and probands, Note that the variants in probands were filtered by population databases only.

Power calculation
-----------------

Using a two-sided paired *t*-test and assuming a genetic relative risk (GRR) equal to 5.8, disease prevalence equal to 0.03, a disease locus frequency equal to 0.01, and a sib recurrence ratio of 2, a sample size of 20 achieves 81% power to detect a mutation difference with a (standardized) effect size of 0.67 between the affected member and the unaffected member. The significance level (alpha) is, in turn, 0.05 \[[@B19],[@B20]\].

Validation
----------

Sanger sequencing was used to validate deleterious variants. Sense and antisense PCR primers for each selected variant were designed using the Primer3 program. The original DNA samples that were used in exome sequencing were served as PCR templates. PCR amplicons were subjected to BigDye sequencing. The resulting sequences were evaluated using CLC Genomics Workbench Program (Cambridge, MA) to confirm the variants called from exome sequences.

Results
=======

Mapping exome data and calling variants
---------------------------------------

Exome sequences were collected via a blood sample from each study participant and mapped to the human genome reference sequence hg19. Variants were called from the mapping data. We focused on single-base, non-synonymous variants that affect protein coding, splicing, and stop gain- or loss mutations, which are reliably detectable by exome analysis \[[@B21]\]. The average exome coverage was 63x, and the average number of variants called was 140,187 per case (Table [1](#T1){ref-type="table"}).

To increase the likelihood that the variants identified in the breast cancer-affected family members are breast cancer-associated, variants in each data set were filtered by: 1) removal of common variants present in human populations. All variants matching to population-derived variant databases (i.e., dbSNP137, ESP6500, and 1000 genomes) were removed; 2) Removal of family-specific normal variants. For the three families in the study, the variants shared between the affected and the unaffected members in the same family were removed. To identify those causing deleterious effects in the affected genes, the remaining variants were analyzed using the Polyphen-2 Program \[[@B18]\]. A total of 337 novel, deleterious variants present only in the affected members of Families I, II, and III were identified at an average of 112 variants per family (Table [2](#T2){ref-type="table"}, Additional files [1](#S1){ref-type="supplementary-material"}: Table S1A, B, C); 689 novel, deleterious variants were identified in the 22 probands at an average of 30 variants per proband (Table [2](#T2){ref-type="table"}, Additional files [2](#S2){ref-type="supplementary-material"}: Table S2A, B). Sanger sequencing validated the mapped variants at a validation rate of 83% (53/64), highlighting the reliability of the variants identified by exome mapping analysis (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1D).

###### 

Novel, deleterious variants detected in breast cancer-affected cases\*

  **Family**      **Total (%)**   **Individual (%)**   **Shared\*\*(%)**
  -------------- --------------- -------------------- -------------------
  Family 1                                                      
   1                   37                 35                   2
   2                   26                 26                   0
   3                   25                 15                  10
   4                   48                 39                   9
   6                   29                 17                  12
   7                   12                 6                    6
   8                   14                 6                    8
  Subtotal          143 (199)          123 (86)             20 (14)
  Family 2                                                      
   1                   22                 13                   9
   2                   15                 5                   10
   3                   21                 9                   12
   4                   21                 12                   9
   5                   16                 8                    8
   6                    8                 2                    6
  Subtotal          66 (100)           47 (71)              19 (29)
  Family 3                                                      
   1                   39                 13                  26
   2                   48                 27                  21
   4                   21                 12                   9
   5                   32                 12                  20
   6                   41                 19                  22
  Subtotal          128 (100)          83 (65)              45 (35)
  Total             337 (100)          253 (75)             84 (25)
  **Probands**                                                  
   1                   35                 10                  25
   2                   58                 22                  36
   3                   74                 28                  46
   4                   77                 49                  28
   5                   70                 28                  42
   6                   41                 16                  25
   7                   31                 24                   7
   8                   43                 27                  16
   9                   51                 19                  32
   10                  61                 30                  31
   11                  70                 35                  35
   12                  51                 12                  39
   13                  55                 15                  40
   14                  60                 30                  30
   15                  51                 31                  20
   16                  41                 31                  10
   17                  32                 18                  14
   18                  57                 25                  32
   19                  58                 18                  40
   20                  47                 23                  24
   21                  33                 25                   8
   22                  34                 22                  12
  Total             689 (100)          568 (82)            121 (18)
  Per proband          30                 26                   6

\*The counts in subtotal and total are the unique number of variants.

\*\*Shared with family members in the families, or shared with other probands.

Novel deleterious variants are mostly family-specific
-----------------------------------------------------

We compared the variants within each family. We observed that 25% of the variants on average (14% in Family I, 29% in Family II, 35% in Family III) were shared in multiple affected members in each family, whereas 75% on average (86% in Family I, 71% in Family II and 65% in Family III) were present only in single affected member in each family (Table [2](#T2){ref-type="table"}). We then compared the shared variants between the three families, and found only 1 variant was shared between Family I and Family II, four variants were shared between Family I and Family III (Figure [2](#F2){ref-type="fig"}A). For the 689 variants identified in the probands, 82% were proband-specific, and only 18% were shared between probands at various frequencies (Figure [2](#F2){ref-type="fig"}B, Additional file [2](#S2){ref-type="supplementary-material"}: Table S2A, S2B). The results indicate that the majority of the novel, deleterious variants identified in the three families and probands are family-specific, i.e., present only in each family but not shared with other families.

![**Comparison of the variants in*BRCAx*families and probands. A**. Comparison in the three families. **B**. Comparison in the probands. The results show that the variants detected in the cancer-affected family members are highly family-specific. The higher rate (18%) of the shared variants in the probands are likely due to the remaining normal variants not filtered in the probands and the larger number of families represented by the probands than the three families.](1471-2407-14-470-2){#F2}

Identification of putative genetic predispositions
--------------------------------------------------

We analyzed the shared mutations between the affected members of the same family, the functional class of the mutated genes, and existing evidence for their contribution to cancer. In doing so, we identified the variants as the putative predispositions in Family I, II, and III, and probands (Table [3](#T3){ref-type="table"}, Additional file [1](#S1){ref-type="supplementary-material"}: Table S1A, S1B, S1C). For Family I, this was the PTEN-Induced Putative Kinase 1 (*PINK1)*; for Family II, these were Lysine (K) Acetyltransferase 6B *(KAT6B)* and Neurogenic Locus Notch Homolog Protein 2 (*NOTCH2)*; and for Family III, this was Phosphorylase Kinase Beta (*PHKB*).

###### 

Putative predispositions in familial breast cancer families and probands

             **Gene**   **Description**                                           **Position**      **Nucleotide**     **Amino acid**   **Type**   **PolyPhen2\***   **Cancer-affected member**   **Frequency**                                 
  ---------- ---------- --------------------------------------------------------- ----------------- ------------------ ---------------- ---------- ----------------- ---------------------------- --------------- ---- ---- ---- ---- ---- ---- ---
  Family 1                                                                                                                                                                                        1               2    3    4    6    7    8     
             GPRIN1     G protein regulated inducer of neurite outgrowth 1        chr5:176026123    c.T713C            p.L238S          Exonic     0.91              D                            \-              \+   \+   \+   \+   \+   \-   5
             PINK1      PTEN induced putative kinase 1                            chr1:20972051     c.960-2A \> G                       Splicing   NA                NA                           \-              \-   \+   \+   \-   \-   \-   2
             POLK       Polymerase (DNA directed) kappa                           chr5:74892737     c.A2219G           p.H740R          Exonic     0.62              P                            \-              \-   \-   \+   \-   \-   \-   1
  Family 2                                                                                                                                                                                        1               2    3    4    5    6          
             KAT6B      K(lysine) acetyltransferase 6B                            chr10:76789128    c.G4546T           p.D1516Y         Exonic     0.95              D                            \-              \+   \+   \+   \+   \+        5
             KAT6B      K(lysine) acetyltransferase 6B                            chr10:76789311    c.C4729T           p.R1577C         Exonic     0.96              D                            \-              \+   \+   \+   \+   \+        5
             NOTCH2     Notch 2                                                   chr1:120459167    c.C6178T           p.R2060C         Exonic     0.99              D                            \-              \-   \+   \-   \-   \+        2
  Family 3                                                                                                                                                                                        1               2    4    5    6               
             NANP       N-acetylneuraminic acid phosphatase                       chr20:25596725    c.A583G            p.I195V          Exonic     0.98              D                            \+              \-   \+   \-   \-             2
             PHKB       phosphorylase kinase, beta                                chr16:47628126    c.1204 + 1G \> T                    Splicing   NA                NA                           \-              \+   \-   \+   \-             2
  Proband                                                                                                                                                                                                                                        
  1          JAKMIP3    Janus kinase and microtubule interacting protein 3        chr10:133955524   c.G1574C           p.G525A          Exonic     1.00              D                                                                           
  2          POLQ       Polymerase (DNA directed), theta                          chr3:121207798    c.A3980C           p.Q1327P         Exonic     1.00              D                                                                           
  3          DUX2       Double homeobox 2                                         chr10:135494906                                       Splicing   NA                NA                                                                          
  4          UBE2L3     Ubiquitin-conjugating enzyme E2L 3                        chr22:21975938    c.G349A            p.E117K          Exonic     0.96              D                            .               .                              
  5          RAD23B     RAD23 homolog B (S. cerevisiae)                           chr9:110087260    c.C1028T           p.P343L          Exonic     0.99              D                            .               .                              
  7          GATA3      GATA binding protein 3                                    chr10:8100630     c.C604T            p.R202C          Exonic     0.92              D                                                                           
  8          KAT6B      K(lysine) acetyltransferase 6B                            chr10:76744854    c.G2390A           p.S797N          Exonic     0.98              D                                                                           
  9          LIG1       Ligase I, DNA, ATP-dependent                              chr19:48637322    c.G1525A           p.E509K          Exonic     0.95              D                            .               .                              
  10         LIG4       Ligase IV, DNA, ATP-dependent                             chr13:108862463   c.G1154A           p.R385K          Exonic     1.00              D                                                                           
  14         NOTCH2     Notch 2                                                   chr1:120529603    c.G854A            p.R285H          Exonic     1.00              D                                                                           
  15         ABL1       c-abl oncogene 1, non-receptor tyrosine kinase            chr9:133729493    c.G122A            p.G41D           Exonic     0.92              D                                                                           
  16         TNK2       Tyrosine kinase, non-receptor, 2                          chr3:195596385    c.C1760T           p.P587L          Exonic     1.00              D                                                                           
  17         NFRKB      Nuclear factor related to kappaB binding protein          chr11:129755398   c.G611A            p.R204H          Exonic     1.00              D                                                                           
  18         NFKBIZ     Nuclear factor of kappa light polypeptide gene enhancer   chr3:101576029                                        Splicing   NA                NA                                                                          
  19         SMG1       SMG1 phosphatidylinositol 3-kinase-related kinase         chr16:18879624    c.C3083T           p.T1028M         Exonic     0.99              D                                                                           
  20         PRKCQ      Protein kinase C, theta                                   chr10:6528042     c.G855C            p.Q285H          Exonic     1.00              D                                                                           
  21         ADRA2A     Adrenoceptor alpha 2A                                     chr10:112838117   c.C363G            p.C121W          Exonic     1.00              D                                                                           
  22         PPFIA4     Protein tyrosine phosphatase, receptor type               chr1:203025582    c.C668T            p.T223M          Exonic     0.92              D                                                                           

D: Probably damaging (score: 0.909-1); P: Possibly damaging (score: 0.447 - 0.908).

*PINK1* is a mitochondrial serine/threonine-protein kinase. Mutation in *PINK1* causes autosomal recessive Parkinson's disease \[[@B22]\]. *KAT6B* is a histone acetyl transferase involved in DNA replication, gene expression and regulation, and epigenetic modification of chromosomal structure \[[@B23]\]. Mutations in *KAT6B* cause multiple neurological diseases \[[@B24]\]. *NOTCH2* is a member of the Notch family involved in controlling cell fate decision. Low Notch activity leads to hyperproliferative activity in breast cancer \[[@B25]\] and mutation in *NOTCH2* causes Hajdu-Cheney syndrome \[[@B26]\]. PHKB regulates the function of phosphorylase kinase \[[@B27]\]. Mutation in *PHKB* causes glycogen storage disease type 9B \[[@B28]\]. Interestingly, a variant in Polymerase (DNA-Directed) Kappa *(POLK)* was present in Family I member \#4. *POLK* is a member of Y family DNA polymerases, and functions by repairing the replication fork passing through DNA lesions \[[@B29]\]. Although we are not able to validate it due to the lack of DNA from the subject's parents, it raises a possibility that this variant could be a *de novo* mutation in this individual. Multiple transcriptional factors were also affected by the mutations in each family. For example, the following transcriptional factors were mutated in Family I: *ZNF335, LRRC66, ZNF417, ZNF587, GTF2I, ZFAND4, EIF4G2, GZF1, CCDC86, ZSCAN18, ZNF546, TAF1L,* and *LRIG3* (Additional file [1](#S1){ref-type="supplementary-material"}: Table S1A).

The variant data from probands show similar patterns as those of the three families (Table [3](#T3){ref-type="table"}). In the 22 probands, four carried variants affecting the genes involved in DNA replication and damaging repair. Those include Polymerase (DNA-directed) Theta (*POLQ)* in Proband \#2, RAD23 Homolog B (*S. cerevisiae*) (*RAD23B)* in Proband \#3, Ligase I DNA, ATP-dependent (*LIG1*) in Proband \#9, and Ligase IV DNA, ATP-dependent *(LIG4)* in Proband \#10. POLQ repairs the apurinic sites \[[@B30]\]. RAD23B plays a role in nucleotide excision repair \[[@B31]\]. *LIG1* ligates nascent DNA of the lagging strand, and a mutation in *LIG1* causes replication errors, genome instability, and cancer \[[@B32]\]. *LIG4* catalyzes double-strand break repair by joining non-homologous ends, and mutation in *LIG4* causes *LIG4* syndrome \[[@B33]\]. Several variants are found in well-known oncogenes and tumor suppressor genes, such as GATA Binding Protein 3 (*GATA3)* in Proband \#7 and Abelson Murine Leukemia Viral Oncogene Homolog 1 (*ABL1*) in Proband \#18. *GATA3* regulates luminal epithelial cell differentiation in the mammary gland \[[@B34],[@B35]\]. The abnormal expression of *GATA3* causes luminal A-type breast cancer \[[@B36]-[@B38]\]. ABL1 is a tyrosine kinase that controls cell differentiation and division. It is involved in (9, 22) translocation, forming BCR-ABL fusion gene in chronic myelogenous leukemia (CML) \[[@B39]\]. Several individual variants in different cases affect the same genes but at different positions. For example, in Proband \#8, a variant in *KAT6B* (c.G1841A/p.S614N) affects the HAT domain at the N terminal, whereas two variants in *KAT6B* in Family II (c.G3997T/p.D1333Y and c.C4180T/p.R1394C) affect the Met-rich domain at the C-terminal. In Proband \#14 and Family II, two different *NOTCH2* variants (c.G854A/p.R285H, c.C6178T/p.R2060C) were present. Multiple variants affect the genes involved in phosphorylation. These include Tyrosine Kinase Non-Receptor 2 (*TNK2*) in proband \#16, Phosphatidylinositol 3 Kinase-Related Kinase (*SMG1*) in Proband \#19, Protein Kinase C Theta (*PRKCQ*) in Proband \#20, and Protein Tyrosine Phosphatase, Receptor Type F *(PPFIZ4)* in Proband \#22.

We also performed an analysis at the pathway level by annotating the mutation-affected genes in the three families using KEGG database (<http://www.genome.jp/kegg/pathway.html>). Certain mutations were identified to affect several functional pathways. For example, the genes mutated in Family I (*ACADVL, AHCY, ALDOA, SGPL1, MAT1A, GALNT8, GGT1*) are involved in metabolic pathways. The genes mutated in Family 2 (*NOTCH2, DUSP16*) are involved in Notch signaling pathway *and* MAPK signaling pathway; genes mutated in Family III (*SLC9A1, ITGAX, ITGAD*) are involved in regulation of actin cytoskeleton.

Discussion
==========

The majority of families with familial breast cancer lack evidence for their genetic predispositions. Efforts in past decade have made slow progress in determining the unknown genetic predispositions. Currently, population-based approach is adapted as the major promising tool to reach the goal \[[@B40]\]. One weakness of this approach is that it can "dilute out the effects of a very strong association in a small subset of the study population" \[[@B41]\]. It requires a large-size disease population of over tens of thousands but the predispositions identified will likely remain very rare in the disease population. Due to the extreme rarity, such genetic predispositions are often difficult to confirm in different disease populations and to distinguish from normal polymorphisms \[[@B5],[@B10]\]. Our study observed the presence of family-specific, novel, deleterious variants, and putative predispositions in the families and probands analyzed. The information implies that, in addition to the population-based approach, a family-based approach provides another option to determine the genetic predisposition.

Based on the higher frequencies of well-known predispositions identified by traditional approaches, the rarity of the predispositions recently identified by population-based approach, and the presence of family-specific, novel, deleterious variants in disease families revealed in our study, we propose a model to explain the genetic predispositions in familial breast cancer (Figure [3](#F3){ref-type="fig"}). In this model, the predisposition in *BRCA1* has the highest frequency in the familial breast cancer population, other known predispositions gradually decrease their frequencies to insignificant levels, and the predispositions for many *BRCAx* familial breast cancers are family-specific. The model explains the difficulty in using traditional and population-based approaches to determine the unknown predispositions, and highlights that applying family-focused approach will be able to determine the genetic predispositions for many *BRCAx* disease families. This model can be further tested in larger number of *BRCAx* familial breast cancer families.

![**A model for the genetic predispositions in familial breast cancer.** The known predisposition in *BRCA1* has the highest sharing frequency in the disease population, other known predispositions decrease their frequencies towards extreme rarity in the disease populations, and the family-specific predispositions are enriched in many disease families without known predispositions. The biggest circle represents the entire genetic predispositions in familial breast cancer. The open circles represent the shared, known predispositions, and the black circles represent the family-specific predispositions.](1471-2407-14-470-3){#F3}

Our study aimed to determine if there are germline mutations present, rather than reach for comprehensive coverage of germline mutations in each family. We achieved this by eliminating all variants matched in population-derived variant databases (i.e., dbSNP137, ESP6500, 1000 genomes) to maximally avoid the variants representing normal polymorphism. Inclusion of such variants as the predisposition candidates, even with the use of certain cut-off such as minor allele frequency (MAF) \<0.01, can increase the sensitivity but decrease the specificity of the variants referred to as putative predispositions.

Assignment of a specific mutation as a true predisposition to a disease family requires solid phenotypic evidence from *in vitro* analysis, cell line tests, search of the literature, bioinformatics data analysis, and animal models. This is best evidenced by determining the *BRCA1* germline mutations as genetic predispositions in breast cancer, in which the definitive conclusion for its contribution to breast cancer is based on the mouse models showing development of breast cancer with the germline mutated *BRCA1*\[[@B42]\]. Our current study aims to provide evidence that the *BRCAx* disease families are enriched with germline damaging mutations, such that focusing on each disease family will be required to determine the genetic predisposition in each family. Indeed, even under strict mapping conditions, large numbers of mutations have been detected in each disease family and probands. While the data provide rich resources to identify the true predisposition for the disease family, the data cannot be considered as true predisposition without further phenotypic and functional evidences.

Conclusions
===========

Our study shows that genetic predispositions in many *BRCAx* familial breast cancer families can be family-specific.
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